|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J. Clin. 67:7–30. 2017.
|
|
2
|
Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie
HY, Wang X, Zou J, Han X and Feng D: Maintenance chemotherapy for
ovarian cancer. In The Cochrane Library; John Wiley, Sons.
(Hoboken, NJ, USA). 2013.
|
|
3
|
Dressman HK, Berchuck A, Chan G, Zhai J,
Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, et al: An
integrated genomic-based approach to individualized treatment of
patients with advanced-stage ovarian cancer. J Clin Oncol.
25:517–525. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jazaeri AA, Awtrey CS, Chandramouli GV,
Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK,
Birrer MJ, et al: Gene expression profiles associated with response
to chemotherapy in epithelial ovarian cancers. Clin Cancer Res.
11:6300–6310. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sudo T: Molecular-targeted therapies for
ovarian cancer: Prospects for the future. Int J Clin Oncol.
17:424–429. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sueblinvong T, Ghebre R, Iizuka Y,
Pambuccian SE, Isaksson Vogel R, Skubitz AP and Bazzaro M:
Establishment, characterization and downstream application of
primary ovarian cancer cells derived from solid tumors. PLOS One.
7:e505192012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Beth A: Weaver How Taxol/paclitaxel kills
cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Buettner R, Mora LB and Jove R: Activated
STAT signaling in human tumors provides novel molecular targets for
therapeutic intervention. Clin Cancer Res. 8:945–954.
2002.PubMed/NCBI
|
|
10
|
Bromberg J and Darnell JE Jr: The role of
STATs in transcriptional control and their impact on cellular
function. Oncogene. 19:2468–2473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Turkson J and Jove R: STAT proteins: Novel
molecular targets for cancer drug discovery. Oncogene.
19:6613–6626. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bowman T, Garcia R, Turkson J and Jove R:
STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duan Z, Foster R, Bell DA, Mahoney J,
Wolak K, Vaidya A, Hampel C, Lee H and Seiden MV: Signal
transducers and activators of transcription 3pathway activation in
drug-resistant ovarian cancer. Clin Cancer Res. 12:5055–5063. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Silver DL, Naora H, Liu J, Cheng W and
Montell DJ: Activated signal transducer and activator of
transcription (STAT) 3: Localization in focal adhesions and
function in ovarian cancer cell motility. Cancer Res. 64:3550–3558.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rosen DG, Mercado-Uribe I, Yang G, Bast RC
Jr, Amin HM, Lai R and Liu J: The role of constitutively active
signal transducer and activator of transcription 3 in ovarian
tumorigenesis and prognosis. Cancer. 107:2730–2740. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yue P, Zhang X, Paladino D, Sengupta B,
Ahmad S, Holloway RW, Ingersoll SB and Turkson J: Hyperactive EGF
receptor, Jaks and Stat3 signaling promote enhanced colony-forming
ability, motility and migration of cisplatin-resistant ovarian
cancer cells. Oncogene. 31:2309–2322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kandala PK and Srivastava SK:
Diindolylmethane suppresses ovarian cancer growth and potentiates
the effect of cisplatin in tumor mouse model by targeting signal
transducer and activator of transcription 3 (STAT3). BMC Med.
10:92012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Colomiere M, Findlay J, Ackland L and
Ahmed N: Epidermal growth factor-induced ovarian carcinoma cell
migration is associated with JAK2/STAT3 signals and changes in the
abundance and localization of alpha6beta1 integrin. Int J Biochem
Cell Biol. 41:1034–1045. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Duan Z, Foster R, Bell DA, Mahoney J,
Wolak K, Vaidya A, Hampel C, Lee H and Seiden MV: Signal
transducers and activators of transcription 3 pathway activation in
drug-resistant ovarian cancer. Clin Cancer Res. 12:5055–5063. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Duan Z, Ames RY, Ryan M, Hornicek FJ,
Mankin H and Seiden MV: CDDO-Me, a synthetic triterpenoid, inhibits
expression of IL-6 and Stat3 phosphorylation in multi-drug
resistant ovarian cancer cells. Cancer Chemother Pharmacol.
63:681–689. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang X, Liu P, Zhang B, Wang A and Yang
M: Role of STAT3 decoy oligodeoxynucleotides on cell invasion and
chemosensitivity in human epithelial ovarian cancer cells. Cancer
Genet Cytogenet. 197:46–53. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sheng WJ, Jiang H, Wu DL and Zheng JH:
Early responses of the STAT3 pathway to platinum drugs are
associated with cisplatin resistance in epithelial ovarian cancer.
Braz J Med Biol Re. 46:650–658. 2013. View Article : Google Scholar
|
|
23
|
Lin L, Benson DM Jr, DeAngelis S, Bakan
CE, Li PK, Li C and Lin J: A small molecule, LLL12 inhibits
constitutive STAT3 and IL-6 induced STAT3 signaling and exhibits
potent growth suppressive activity in human multiple myeloma cells.
Int J Cancer. 130:1459–1469. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin L, Hutzen B, Li PK, Ball S, Zuo M,
DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, et al: A Novel
Small Molecule, LLL12, Inhibits STAT3 phosphorylation and
activities and exhibits potent growth-suppressive activity in human
cancer cells. Neoplasia. 12:39–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang J, Zaman MM, Vlasakov I, Roy R, Huang
L, Martin CR, Freedman SD, Serhan CN and Moses MA: Adipocytes
promote ovarian cancer chemoresistance. Sci Rep. 9:133162019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma S, Tan W, Du B, Liu W, Li W, Che D and
Zhang G: Oridonin effectively reverses cisplatin drug resistance in
human ovarian cancer cells via induction of cell apoptosis and
inhibition of matrix metalloproteinase expression. Mol Med Rep.
13:3342–3348. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fu S, Chen X, Lin HJ and Lin J: Inhibition
of interleukin 8/CXC chemokine receptor 1/2 signaling reduces
malignant features in human pancreatic cancer cells. Int J Oncol.
53:349–357. 2018.PubMed/NCBI
|
|
29
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bristow RE and Chi DS: Platinum-based
neoadjuvant chemotherapy and interval surgical cytoreduction for
advanced ovarian cancer: A meta-analysis. Gynecol Oncol.
103:1070–1076. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Arora S, Bisanz KM, Peralta LA, Basu GD,
Choudhary A, Tibes R and Azorsa DO: RNAi screening of the kinome
identifies modulators of cisplatin response in ovarian cancer
cells. Gynecol Oncol. 118:220–227. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kang J, D'Andrea AD and Kozono D: A DNA
repair pathway-focused score for prediction of outcomes in ovarian
cancer treated with platinum-based chemotherapy. J Natl Cancer
Inst. 104:670–681. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang M, Page C, Reynolds RK and Lin J:
Constitutive activation of stat 3 oncogene product in human ovarian
carcinoma cells. Gynecol Oncol. 79:67–73. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Burke WM, Jin X, Lin HJ, Huang M, Liu R,
Reynolds RK and Lin J: Inhibition of constitutively active Stat3
suppresses growth of human ovarian and breast cancer cells.
Oncogene. 20:7925–7934. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Han Z, Feng J, Hong Z, Chen L, Li W, Liao
S, Wang X, Ji T, Wang S, Ma D, et al: Silencing of the STAT3
signaling pathway reverses the inherent and induced chemoresistance
of human ovarian cancer cells. Biochem Biophys Res Commun.
435:188–194. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Turkson J, Ryan D, Kim JS, Zhang Y, Chen
Z, Haura E, Laudano A, Sebti S, Hamilton AD and Jove R:
Phosphotyrosyl peptides block Stat3-mediated DNA binding activity,
gene regulation, and cell transformation. J Biol Chem.
276:45443–45455. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Burke TR Jr, Yao ZJ, Liu DG, Voigt J and
Gao Y: Phosphoryltyrosyl mimetics in the design of peptide-based
signal transduction inhibitors. Biopolymers. 60:32–44. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Iwamaru A, Szymanski S, Iwado E, Aoki H,
Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, et al: A
novel inhibitor of the STAT3 pathway induces apoptosis in malignant
glioma cells both in vitro and in vivo. Oncogene. 26:2435–2444.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Siddiquee K, Zhang S, Guida WC, Blaskovich
MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence
NJ, et al: Selective chemical probe inhibitor of Stat3, identified
through structure-based virtual screening, induces antitumor
activity. Proc Natl Acad Sci USA. 104:7391–7396. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Song H, Wang R, Wang S and Lin J: A
low-molecular-weight compound discovered through virtual database
screening inhibits Stat3 function in breast cancer cells. Proc Natl
Acad Sci USA. 102:4700–4705. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schust J, Sperl B, Hollis A, Mayer TU and
Berg T: Stattic: A small molecule inhibitor of STAT3 activation and
dimerization. Chem Biol. 13:1235–1242. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Duan Z, Bradner JE, Greenberg E, Levine R,
Foster R, Mahoney J and Seiden MV: SD-1029 inhibits signal
transducer and activator of transcription 3nuclear translocation.
Clin Cancer Res. 12:6844–6852. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wei CC, Ball S, Lin L, Liu A, Fuchs JR, Li
PK, Li C and Lin J: Two small molecule compounds, LLL12 and FLLL32,
exhibit potent inhibitory activity on STAT3 in human
rhabdomyosarcoma cells. Int J Oncol. 38:279–285. 2011.PubMed/NCBI
|
|
44
|
Onimoe GI, Liu A, Lin L, Wei CC, Schwartz
EB, Bhasin D, Li C, Fuchs JR, Li PK, Houghton P, et al: Small
molecules, LLL12 and FLLL32, inhibit STAT3and exhibit potent growth
suppressive activity in osteosarcoma cells and tumor growth in
mice. Invest New Drugs. 30:916–926. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ball S, Li C, Li PK and Lin J: The Small
Molecule, LLL12, Inhibits STAT3 Phosphorylation and Induces
Apoptosis in Medulloblastoma and Glioblastoma Cells. PLoS One.
6:e188202011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Couto JI, Bear MD, Lin J, Pennel M, Kulp
SK, Kisseberth WC and London CA: Biologic activity of the novel
small molecule STAT3 inhibitor LLL12 against canine osteosarcoma
cell lines. BMC Vet Res. 8:2442012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hamilton TC, Young RC and Ozols RF:
Experimental model systems of ovarian cancer: Applications to the
design and evaluation of new treatment approaches. Semin Oncol.
11:285–298. 1984.PubMed/NCBI
|
|
48
|
Blayney JK, Davison T, McCabe N, Walker S,
Keating K, Delaney T, Greenan C, Williams AR, McCluggage WG,
Capes-Davis A, et al: Prior knowledge transfer across
transcriptional data sets and technologies using compositional
statistics yields new mislabelled ovarian cell line. Nucleic Acids
Res. 44:e1372016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bratcher NA, Frost DJ, Hickson J, Huang X,
Medina LM, Oleksijew A, Ferguson DC and Bolin S: Effects of
buprenorphine in a preclinical orthotopic tumor model of ovarian
carcinoma in female CB17 SCID Mice. J Am Assoc Lab Anim Sci.
58:583–588. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Capo-Chichi CD, Cai KQ and Xu XX:
Overexpression and cytoplasmic localization of caspase-6 is
associated with lamin A degradation in set of ovarian cancers.
Biomark Res. 6:302018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Fang Z, Li T, Chen W, Wu D, Qin Y, Liu M,
Wu G, He L, Li H and Gu H: Gab2 promotes cancer stem cell like
properties and metastatic growth of ovarian cancer via
downregulation of miR-200c. Exp Cell Res. 382:1114622019.
View Article : Google Scholar : PubMed/NCBI
|
